Close menu




January 26th, 2022 | 13:34 CET

Valneva, Perimeter Medical Imaging AI, MorphoSys - This is where it gets exciting!

  • Pharma
  • Biotech
  • Innovations
Photo credits: pixabay.com

The Corona pandemic still has the world firmly in its grip. The number of new infections is skyrocketing. Nevertheless, the chances are good that the pandemic can be brought under control by means of numerous vaccines. But Corona is not the only scourge. Numerous research efforts are focused on diagnosing, treating and curing cancer. Here, innovative AI-based technologies are increasingly being used to help save lives and significantly reduce costs for the healthcare system.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: PERIMETER MED.IMAG.AI | CA71385D1078 , VALNEVA SE EO -_15 | FR0004056851 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Valneva - Omicron variant under control

    The share of the specialty vaccine manufacturer has shown a wide range of fluctuation in recent weeks. The latest results on the vaccine's efficacy against the Omicron variant were encouraging. It was proven that with the administration of three doses of the vaccine VLA2001, the Omicron variant of COVID-19 could be neutralized. Share prices responded positively. Analysts also continue to see potential, with experts at Kepler Cheuvreux issuing a price target for the stock of EUR 24, an upside of over 60%.

    Valneva focuses on the development and marketing of prophylactic vaccines against infectious diseases with a high unmet medical need. Prophylactic vaccines activate the immune system to protect against infectious diseases. The Company's inactivated corona vaccines are the focus of media interest. Application for approval has recently been made to the European Medicines Agency (EMA), and initial orders have been received. Inactivated vaccines have been used in medicine for a long time, e.g. against tetanus, whooping cough, diphtheria or as influenza vaccines, and are regarded as established. However, as yet, no inactivated vaccines have been approved as corona vaccines in the EU.

    Perimeter Medical Imaging AI - Disruptive potential

    Around 10 million people die of cancer worldwide each year. The fight against this insidious disease also costs over USD 1 trillion annually. Founded in Canada in 2013, Perimeter Medical Imaging AI delivers an effective and innovative approach to fighting cancer.

    The medical technology company aims to transform cancer surgery with ultra-high resolution, real-time advanced imaging tools to address unmet medical needs. The Canadians' solutions enable examinations of tissue microstructures during surgical procedures using real-time, software-based visualization. This technology thus provides surgeons, radiologists and pathologists with important results during the examination that would otherwise take several days using traditional examination methods. It leads to improved results for patients, while representing potential savings for the healthcare sector.

    To stem further growth, the Canadians conducted a capital increase of CAD 43.4 million in mid-December. Also, late last year, Perimeter announced the first commercial installation of its Perimeter S-Series high-resolution, real-time OCT imaging system at a North Texas hospital. With solid funding and great disruptive potential, the Company's current market cap of CAD 155 million makes it an exciting story.

    MorphoSys - Money Cruncher

    Three quarters! That is how much MorphoSys shareholders have lost in the last 12 months. The stock market value of the biotech company has thus dipped below the EUR 1 billion mark. At the beginning of the year, the stock was dealt a further blow in view of a disappointing revenue outlook and high planned expenditure on research and development. Even though many analysts believe the stock has significant upside potential, the experts are continuing to slash their price targets.

    The South German company is in the process of reinventing itself and is currently undergoing a transformation from a contract researcher for the pharmaceutical industry to a developer of its own drugs. In this context, the Company completed the multi-billion dollar acquisition of US epigenetics specialist Constellation Pharma last summer. Royalty Pharma subscribed for shares with an equivalent value of EUR 100 million and will receive various royalties in the future.

    MorphoSys is thus betting on the future and taking high risks in the coming years. According to management, the Company will not be back in the black until 2026, as milestone payments will be low, whereas research and development expenses will increase significantly, with EUR 300 to 325 million budgeted for 2022.

    However, the sales expectation of the first proprietary cancer drug Monjuvi of USD 135 million in the current year, which was announced in January, disappointed many market participants. CFO Lee is nevertheless unabashedly optimistic and recently announced plans to launch two proprietary cancer drugs in 2025.


    The healthcare market remains huge. The companies mentioned are targeting different areas. Corona is the topic of the hour, so vaccine manufacturers like Valneva are still in focus. Cancer detection and cure is a field with a high addressable market volume. MorphoSys should be treated with caution for the time being in the course of the transformation process. Major disruptive potential is offered by the solutions of Perimeter Medical Imaging AI.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Fabian Lorenz on July 8th, 2025 | 07:05 CEST

    Rheinmetall above EUR 2,000? Bayer shares exhausted? NetraMark Holdings with lots of upside potential!

    • Biotechnology
    • Pharma
    • Defense

    It seems only a matter of time before Rheinmetall shares break through the EUR 2,000 barrier. Increasingly, analysts are setting price targets above this mark. And operations are running smoothly, as demonstrated by the latest ammunition order and the Company's participation in the German government's billion-euro investment program. NetraMark, on the other hand, does not have to invest billions in research and development. The AI specialist is still an insider tip. However, the first study is now available, and analysts anticipate over 50% upside potential. In contrast, analysts see the end of the price fireworks at Bayer. Are they right?

    Read

    Commented by Nico Popp on July 4th, 2025 | 07:10 CEST

    Biotech stocks with a safety net and double bottom: Vidac Pharma, BioNTech, and Gilead Sciences

    • Biotechnology
    • Biotech
    • Pharma

    For many years, biotech stocks were considered speculative bets on a single, all-important active ingredient. For seasoned biotech investors, it was once clear that there was little gray area between multiplication and total loss. But the biotech landscape has changed. Innovative technologies and modern processes ensure that even smaller biotech companies have several arrows in their quiver that can hit the mark. We explain what has changed in the biotech sector and what opportunities for collaboration could exist between BioNTech, Gilead Sciences, and Vidac Pharma.

    Read

    Commented by André Will-Laudien on July 4th, 2025 | 07:05 CEST

    Lightning on the horizon in the biotech sector: Refinancing on the rise! Keep an eye on Formycon, PanGenomic Health, Bayer, and Novo Nordisk

    • Biotechnology
    • Biotech
    • healthtech
    • Pharma

    In the first half of 2025, the biotech sector demonstrated resilience and innovation despite macroeconomic uncertainties. Venture capital financing reached an impressive USD 6.5 billion, with a focus on companies with clinically validated data. Large financing deals such as the USD 365 million for Pathos AI underscore the strategic investor focus on AI and digitalization. The IPO market remains highly selective, but strong stock market debuts such as that of Caris Life Sciences are sending positive signals. At the same time, the M&A sector is booming with billion-dollar acquisitions by pharmaceutical giants such as J&J and Novo. So far in 2025, the biotech sector has demonstrated targeted capital allocation, dynamic consolidation, and growing confidence in medical breakthroughs. Here are a few ideas for a balanced portfolio of opportunities.

    Read